Jeffrey S. Hatfield

    Jeffrey Hatfield
    Jeffrey S. Hatfield

    Mr. Hatfield is a senior life sciences executive who has led businesses in both the emerging biotechnology and global Fortune 500 pharma sectors. Mr. Hatfield joined Zafgen in 2017 as Chief Executive Officer and a member of the Company’s Board of Directors. Most recently, he served as President and Chief Executive Officer of Vitae Pharmaceuticals, Inc., where he led the growth of the company from start-up in 2004, until its unsolicited acquisition by Allergan plc in 2016. Prior to Vitae, Mr. Hatfield was a senior executive at Bristol-Myers Squibb Corporation (BMS) for twenty years, where he held roles of increasing responsibility including Senior Vice President, Immunology and Virology Divisions; President, BMS-Canada, and Vice President of US Market Access. During his career at BMS, he was directly involved with several successful commercial launches, including Plavix©, Pravachol©, Glucophage© and Atripla©.

    Mr. Hatfield currently serves on the boards of aTyr Pharmaceuticals, Inc., miRagen Therapeutics, Inc., and InVivo Therapeutics Holdings Corp. He previously served on the board of Ambit Biosciences, Inc. before its acquisition by Daiichi-Sankyo and on the board and Executive Committee of BIO (the Biotechnology Innovation Organization).

    Mr. Hatfield earned an M.B.A. from The Wharton School, University of Pennsylvania, and a B.S. from the College of Pharmacy, Purdue University, where he currently serves as an Adjunct Professor for doctoral students, and as a member of the Dean’s Advisory Council.

    Jeffrey S. Hatfield

      Jeffrey Hatfield
      Jeffrey S. Hatfield
      Chief Executive Officer

      Mr. Hatfield is a senior life sciences executive who has led businesses in both the emerging biotechnology and global Fortune 500 pharma sectors. Mr. Hatfield joined Zafgen in 2017 as Chief Executive Officer and a member of the Company’s Board of Directors. Most recently, he served as President and Chief Executive Officer of Vitae Pharmaceuticals, Inc., where he led the growth of the company from start-up in 2004, until its unsolicited acquisition by Allergan plc in 2016. Prior to Vitae, Mr. Hatfield was a senior executive at Bristol-Myers Squibb Corporation (BMS) for twenty years, where he held roles of increasing responsibility including Senior Vice President, Immunology and Virology Divisions; President, BMS-Canada, and Vice President of US Market Access. During his career at BMS, he was directly involved with several successful commercial launches, including Plavix©, Pravachol©, Glucophage© and Atripla©.

      Mr. Hatfield currently serves on the boards of aTyr Pharmaceuticals, Inc., miRagen Therapeutics, Inc., and InVivo Therapeutics Holdings Corp. He previously served on the board of Ambit Biosciences, Inc. before its acquisition by Daiichi-Sankyo and on the board and Executive Committee of BIO (the Biotechnology Innovation Organization).

      Mr. Hatfield earned an M.B.A. from The Wharton School, University of Pennsylvania, and a B.S. from the College of Pharmacy, Purdue University, where he currently serves as an Adjunct Professor for doctoral students, and as a member of the Dean’s Advisory Council.